BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24411578)

  • 1. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
    Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
    Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical versus Medical Treatment of Ocular Surface Squamous Neoplasia: A Cost Comparison.
    Moon CS; Nanji AA; Galor A; McCollister KE; Karp CL
    Ophthalmology; 2016 Mar; 123(3):497-504. PubMed ID: 26686965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Sinha B; Kumar R
    Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
    Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
    Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
    Boehm MD; Huang AJ
    Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of ocular surface squamous neoplasia recurrence after excisional surgery.
    Galor A; Karp CL; Oellers P; Kao AA; Abdelaziz A; Feuer W; Dubovy SR
    Ophthalmology; 2012 Oct; 119(10):1974-81. PubMed ID: 22704832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification.
    Shields CL; Kaliki S; Kim HJ; Al-Dahmash S; Shah SU; Lally SE; Shields JA
    Cornea; 2013 Mar; 32(3):248-56. PubMed ID: 22580436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological characteristics of ocular surface squamous neoplasia in an Asian population.
    Kim BH; Kim MK; Wee WR; Oh JY
    Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2569-73. PubMed ID: 24006080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
    Sturges A; Butt AL; Lai JE; Chodosh J
    Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
    Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
    Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review.
    Karp CL; Galor A; Chhabra S; Barnes SD; Alfonso EC
    Ophthalmology; 2010 Dec; 117(12):2241-6. PubMed ID: 20619462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
    Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
    Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium.
    Oellers P; Karp CL; Sheth A; Kao AA; Abdelaziz A; Matthews JL; Dubovy SR; Galor A
    Ophthalmology; 2013 Mar; 120(3):445-450. PubMed ID: 23107578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
    Zaki AA; Farid SF
    Cornea; 2009 Oct; 28(9):986-8. PubMed ID: 19724215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
    Karp CL; Moore JK; Rosa RH
    Ophthalmology; 2001 Jun; 108(6):1093-8. PubMed ID: 11382635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
    Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
    Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
    Schechter BA; Schrier A; Nagler RS; Smith EF; Velasquez GE
    Cornea; 2002 Jan; 21(1):6-11. PubMed ID: 11805499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
    Holcombe DJ; Lee GA
    Am J Ophthalmol; 2006 Oct; 142(4):568-71. PubMed ID: 17011846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases.
    Yousef YA; Finger PT
    Ophthalmology; 2012 Feb; 119(2):233-40. PubMed ID: 22189448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery Versus Interferon Alpha-2b Treatment Strategies for Ocular Surface Squamous Neoplasia: A Literature-Based Decision Analysis.
    Siedlecki AN; Tapp S; Tosteson AN; Larson RJ; Karp CL; Lietman T; Zegans ME
    Cornea; 2016 May; 35(5):613-8. PubMed ID: 26890663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.